Published in Cancer on March 01, 2006
Peritoneal mesothelioma: a review. MedGenMed (2007) 2.01
Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg (2007) 1.66
Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol (2010) 1.12
Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol (2010) 1.05
Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol (2011) 0.89
Morbidity and mortality of 109 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC) performed at a community hospital. World J Surg (2010) 0.89
Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination. Onco Targets Ther (2013) 0.85
Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg (2014) 0.85
Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. Surg Endosc (2013) 0.84
Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer (2014) 0.83
Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol (2013) 0.83
Rare diaphragmatic complications following cytoreductive surgery and HIPEC: report of two cases. Surg Today (2012) 0.83
Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol (2012) 0.82
A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg (2010) 0.82
Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: preliminary results. ISRN Surg (2011) 0.81
Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary? J Oncol (2014) 0.81
Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis. J Exp Clin Cancer Res (2011) 0.81
Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico. ISRN Oncol (2011) 0.81
Pulmonary Complications following Cytoreductive Surgery and Perioperative Chemotherapy in 147 Consecutive Patients. Gastroenterol Res Pract (2012) 0.80
Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival. Ann Surg Oncol (2013) 0.80
Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India. J Clin Diagn Res (2015) 0.79
Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. Indian J Surg Oncol (2016) 0.78
Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study. Tech Coloproctol (2011) 0.77
Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol (2016) 0.77
Peritoneal carcinomatosis of gastrointestinal tumors: where are we now? World J Gastroenterol (2014) 0.76
Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol (2013) 0.76
A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Can J Surg (2009) 0.75
Limited, local, extracolonic spread of mucinous appendiceal adenocarcinoma after perforation with formation of a malignant appendix-to-sigmoid fistula: Case report and literature review. World J Gastroenterol (2016) 0.75
Epididymitis following Cytoreductive Surgery with Intraperitoneal Oxaliplatin Chemotherapy: Two Case Reports. Case Rep Oncol (2016) 0.75
Rhabdomyolysis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report. Case Rep Oncol (2013) 0.75
Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details. Ulus Cerrahi Derg (2015) 0.75
Cytoreductive Surgery and Peritonectomy Procedures. Indian J Surg Oncol (2016) 0.75
Tonic-Clonic Seizure following Cytoreductive Surgery with Intraperitoneal Oxaliplatin: A Case Report and Review of the Literature. Case Rep Oncol (2016) 0.75
Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery. Medicine (Baltimore) (2016) 0.75
Gastric perforation following cytoreductive surgery and perioperative intraperitoneal chemotherapy: a case series of six. World J Surg Oncol (2017) 0.75
Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol (2016) 0.75
Safe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstruction. J Transl Med (2013) 0.75
Inferior vena cava enteric fistula due to unresected colorectal metastasis. World J Emerg Surg (2015) 0.75
Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan. Medicine (Baltimore) (2017) 0.75
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol (2011) 2.35
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. Ann Surg Oncol (2002) 1.97
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol (2007) 1.56
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol (2004) 1.51
Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol (2007) 1.46
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol (2008) 1.41
Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol (2009) 1.38
Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol (2008) 1.28
Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol (2008) 1.12
Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 1.12
Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg (2012) 1.12
Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses (2011) 1.11
Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol (2008) 1.10
Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. Int J Radiat Oncol Biol Phys (2007) 1.09
Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol (2010) 1.07
Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol (2010) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg (2009) 1.03
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2007) 1.03
Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2008) 1.02
Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC). Hum Mutat (2006) 1.01
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol (2008) 1.01
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol (2014) 1.00
Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol (2010) 0.98
Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.98
Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol (2007) 0.98
Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2005) 0.95
Colobronchial fistula: an unusual complication after peritonectomy and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo (2009) 0.95
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol (2003) 0.95
The nutritional risk in oncology: a study of 1,453 cancer outpatients. Support Care Cancer (2012) 0.95
Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol (2006) 0.94
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol (2014) 0.93
The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol (2008) 0.91
Consensus statement on peritoneal mesothelioma. J Surg Oncol (2008) 0.90
Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer (2005) 0.89
Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol (2012) 0.89
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer (2013) 0.88
Complete anemia reversal after surgical excision of mesenteric hyaline-vascular unicentric Castleman disease. Can J Surg (2009) 0.88
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol (2008) 0.88
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer (2010) 0.86
The eligibility for local-regional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.85
Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res (2003) 0.85
Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care. J Surg Oncol (2008) 0.84
Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol (2008) 0.84
Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol (2011) 0.84
Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg (2012) 0.84
Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer. Surgery (2004) 0.84
American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol (2014) 0.84
Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg (2002) 0.83
The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2013) 0.83
Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol (2006) 0.82
The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am (2012) 0.81
Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol (2010) 0.81
Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol (2012) 0.81
Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol (2009) 0.81
Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2007) 0.80